Alpha-MSH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Maggots in a single day would clean a wound much better than any agents we had at our command ... I am sure I saved many lives by their use. He recorded a high survival rate in patients he treated with maggots. During World War I, orthopedic surgeon William S. Baer recorded the case of a soldier left for several days on the battlefield who had sustained compound fractures of the femur and large flesh wounds. The soldier arrived at the hospital with maggots infesting his wounds but had no fever or other signs of infection and survived his injuries, which would normally have been fatal. After the war, Baer began using maggot therapy at Boston Children's Hospital in Massachusetts. There were reports that American prisoners of war of the Japanese in World War II resorted to maggot therapy to treat severe wounds. A survey of US Army doctors published in 2013 found that 10% of them had used maggot therapy.
== Contraindications == Contraindications of elagolix include pregnancy, known osteoporosis, severe hepatic impairment, and concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors such as ciclosporin and gemfibrozil. Elagolix may increase the risk of miscarriage in early pregnancy. Women should avoid pregnancy while taking elagolix, for instance by using birth control, and should discontinue the medication if they become or wish to become pregnant. Elagolix should not be used in women with osteoporosis because it may increase the risk of further bone loss. Severe hepatic impairment is associated with 7-fold increased exposure to elagolix, which may increase the risk of bone loss. In women with moderate hepatic impairment, which is associated with 3-fold increased exposure to elagolix, the medication at 200 mg twice per day should not be used, while 150 mg once per day should be used for no more than 6 months. OATP1B1 inhibitors are likely to greatly increase exposure to elagolix similarly to moderate to severe hepatic impairment. Combined birth control is not contraindicated with elagolix, but because of the estrogen component, is expected to decrease the effectiveness of elagolix in the treatment of endometriosis, and hence is not recommended. Other forms of birth control, such as non-hormonal birth control, can be used instead. Elagolix is not contraindicated in women who are breastfeeding, but it is unknown whether the medication is excreted in breast milk or if it has adverse effects on milk production or the breastfed child.
== Diagnosis == Diagnosis typically occurs in the first few years of life and should be confirmed with a review of symptoms as well as genetic testing with targeted panels that include the ALMS1 gene as well as other ciliopathies, retinal diseases, cardiomyopathy, and obesity. Typically, the first symptoms to be observed are nystagmus, photophobia, impaired vision, and/or infantile cardiomyopathy within the first two years of life. Obesity and/or sensorineural hearing loss are often next and should be followed by genetic/molecular testing to try and identify two pathogenic variants of ALMS1 to confirm or deny the presence of the disease. However, the rarity of the disease, variability of symptoms, and lack of experts can make diagnosis very difficult. Additionally, since it can be difficult to identify both biallelic pathogenic variants in the ALMS1 gene, there is existing diagnostic criteria as shown below.
== Behavior and diet == It is a secretive species and is seldom encountered by humans. It is active by day and night, though it is usually more active by day. This largely aquatic snake spends most of its time in the water. It is an excellent swimmer and is capable of remaining underwater for up to 10 minutes and diving to depths of 25 m (82 ft). It is a slow mover on land, and it tends to hide among rocks, in holes, or overhanging tree roots at the shoreline. It also makes use of any man-made structures, such as bridges and jetties, to hide. It is generally not aggressive, and if approached in water, it will swim away swiftly and on land will attempt to escape into water. If threatened on land, it will rear up and spread its narrow, yet prominent hood and it may hiss loudly, but it tends not to make any forward movements. It will only bite when provoked. It preys almost exclusively on fish. It may also prey on frogs, toads, and other amphibians.
== V == vaccine – vacuole – varicella-zoster virus – vascular cambium – vascular tissue – vein – vertebrate – vesicle – vesicular stomatitis virus – vestibular system – vicariance – virology – viral classification – virus – viral evolution – viridamide – visible light – vision – vitamin - Viroid
Sources: en.wikipedia.org
Back pressure (or backpressure) is the term for a resistance to the desired flow of fluid through pipes. Obstructions or tight bends create backpressure via friction loss and pressure drop. In distributed systems in particular event-driven architecture, back pressure is a technique to regulate flow of data, ensuring that components do not become overwhelmed.
According to the International Society for Plastination, the Epoxy E 12 procedure is used "for thin, transparent, and firm body and organ slices", while the Polyester P 35 (P 40) preserves "semitransparent and firm brain slices". Samples are prepared for fixation through the first method by deep freezing, while the second method works best following 4–6 weeks of preparation in a formaldehyde mixture.
== Early life and education == Gavin Christopher Newsom was born on October 10, 1967, in San Francisco, California, to Tessa Thomas (née Menzies) and William Alfred Newsom III, a state appeals court judge and attorney for Getty Oil. He is a descendant of the Newsom family of architects active in early 20th century California, who originally came from Canada. William Newsom was a close friend of billionaire heir Gordon Getty, who repeatedly supported Gavin's career. William Newsom would also for a time help manage the Getty Trust. A fourth-generation San Franciscan, Newsom comes from a prominent family. His maternal great-grandfather Thomas Addis was a nephrologist and professor of medicine at Stanford University noted for his research on kidney disease. Newsom is a second cousin twice removed of musician Joanna Newsom, and his aunt Barbara Newsom was married to Ron Pelosi, the brother-in-law of former House speaker Nancy Pelosi. Newsom's parents divorced in 1971 when he was three years old, leaving his mother, Tessa, to raise him and his younger sister, Hilary Newsom Callan, largely on her own. Tessa worked three jobs—often as a waitress, bookkeeper, and secretary—to support the family, and Newsom has cited her as shaping his work ethic. Newsom has called his childhood challenging, shaped in part by financial instability and his struggle with "pretty severe" dyslexia, a condition he still has. Newsom's education began at École Notre Dame des Victoires, a French-American bilingual Catholic school in San Francisco that he attended for kindergarten and first grade.
== Applications == Cell biology utilizes tools that allow manipulation and visualization of proteins in living cells. An important example is the use of fluorescent proteins, such as the green fluorescent protein (GFP) or yellow fluorescent protein (YFP). Molecular biology methods allow these fluorescent proteins to be introduced and expressed in living cells as fusion proteins. However, the photo-physical properties of the fluorescent proteins are generally not suited for single-molecule spectroscopy. Fluorescent proteins have, in comparison to commercially available dyes, a much lower fluorescence quantum yield and are quickly destroyed upon excitation with a focused laser beam (photobleaching). The SNAP-tag® protein is an engineered version of the ubiquitous mammalian enzyme AGT, encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. SNAP-tag was obtained using a directed evolution strategy, leading to a hAGT variant that accepts O6-benzylguanine derivatives instead of repairing alkylated guanine derivatives in damaged DNA. An orthogonal tag, called CLIP-tag™, was further engineered from SNAP-tag to accept O2-benzylcytosine derivatives as substrates, instead of O6-benzylguanine. Therefore, Clip-tag- and SNAP-tag-fused proteins can be labeled simultaneously in the same cells. A split-SNAP-tag version suitable for protein complementation assay and protein-protein interaction studies was later developed.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.